Individualising biologic therapy for paediatric severe asthma: A comparative review of all five approved agents, real-world evidence, and a biomarker-guided clinical decision algorithm
Therapeutic Advances in Respiratory Disease · 2026
DOI: 10.1177/17534666261497070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2026. Verfasst von Xiaowei Yao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Therapy. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Severe asthma affects 5–10% of children with asthma yet accounts for disproportionate morbidity and healthcare utilisation. The recent expansion of biologic therapies—targeting IgE, IL-5, IL-4/13, TSLP, and IL-5 receptor α—has transformed management but introduced complexity into clinical decision-making. This review provides a comprehensive, comparative analysis of currently approved biologic agents for paediatric severe asthma, with emphasis on efficacy, safety, biomarker-guided selection, and practical implementation. We searched PubMed/MEDLINE (2015–2026) for randomised controlled trials, systematic reviews, and observational studies evaluating biologic therapies in children and adolescents with severe asthma, using a narrative synthesis approach.Five biologic agents are currently approved for paediatric severe asthma. Omalizumab (anti-IgE) reduces exacerbations by 38–50% in allergic asthma (≥6 years). Mepolizumab (anti-IL-5) reduces exacerbations by 27% (rate ratio 0.73; 95% CI 0.56–0.96) in eosinophilic asthma in children and adolescents aged 6–17 years (MUPPITS-2). Dupilumab (anti-IL-4Rα) reduces exacerbations by 59% and improves lung function in children 6–11 years (VOYAGE). Tezepelumab (anti-TSLP) reduces exacerbations by 56% and is the first agent effective in T2-low phenotypes (≥12 years; NAVIGATOR). Benralizumab (anti-IL-5Rα) induces near-complete eosinophil depletion with extended every-8-week maintenance dosing; FDA approval was extended to children ≥6 years in April 2024 based on the TATE trial (SIROCCO/CALIMA/BORA/TATE). Safety profiles are generally favourable; dupilumab-associated conjunctivitis and omalizumab-related anaphylaxis require specific monitoring protocols.Biologic therapies have ushered paediatric severe asthma into the precision medicine era. Dupilumab and tezepelumab demonstrate robust efficacy across multiple phenotypes, while biomarker assessment enables rational, individualised selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, China.
ORCID-Profile: Yang Yu
Zitieren
APA
Yao, X., & Yu, Y. (2026). Individualising biologic therapy for paediatric severe asthma: A comparative review of all five approved agents, real-world evidence, and a biomarker-guided clinical decision algorithm. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666261497070
Vancouver
Yao X, Yu Y. Individualising biologic therapy for paediatric severe asthma: A comparative review of all five approved agents, real-world evidence, and a biomarker-guided clinical decision algorithm. Therapeutic Advances in Respiratory Disease. 2026. doi:10.1177/17534666261497070
BibTeX
@article{Yao2026,
author = {Yao, Xiaowei and Yu, Yang},
title = {Individualising biologic therapy for paediatric severe asthma: A comparative review of all five approved agents, real-world evidence, and a biomarker-guided clinical decision algorithm},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
doi = {10.1177/17534666261497070}
}
EUVIMED